劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

交易中 09-03 14:57:34

27.560

-0.740

-2.61%

最高28.900	最低27.000	成交量49.40万
今开28.900	昨收28.300	日振幅6.71%
总市值105.83亿	流通市值97.01亿	总股本3.84亿
成交额1,357万	换手率0.14%	流通股本3.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":27.56,"timestamp":1788418580843,"preClose":28.3,"halted":0,"volume":494000,"delay":0,"changeRate":-0.026148409893993002,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"交易中","change":-0.74,"latestTime":"09-03 14:57:34","open":28.9,"high":28.9,"low":27,"amount":13570601,"amplitude":0.067138,"askPrice":27.6,"askSize":1600,"bidPrice":27.56,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788423000000},"marketStatusCode":2,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":28.3,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.366084,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"1197279411","title":"劲方医药-B：9月2日回购3.90万股，耗资约107.63万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197279411","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197279411?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:21","pubTimestamp":1788348071,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年9月2日发布翌日披露报表，宣布在香港联交所场内回购H股3.90万股，占公司已发行股本的0.011%。本次回购价格区间每股介乎HKD 27.40至HKD 27.74，合计动用资金约HKD 1,076,308。根据公告，公司于2026年5月11日通过了购回授权，授权总数为37,036,663股，此次购回数量为39,000股，占购回授权通过当日已发行股本的0.011%。公告显示，劲方医药-B已遵守香港联交所证券上市规则及相关法律法规。公告由联席公司秘书张巍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药-B：9月2日回购3.90万股，耗资约107.63万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815269","title":"劲方医药-B(02595)9月2日斥资107.63万港元回购3.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815269","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664815269?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:06","pubTimestamp":1788347190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月2日，该公司斥资107.63万港元回购3.9万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1161","159938","02595","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106227011","title":"劲方医药-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1106227011","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106227011?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:01","pubTimestamp":1788346918,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年9月2日发布2026年8月股份变动月报表。根据公告，截至2026年8月31日，公司注册资本总额为人民币38,396,663元，已发行股份总数合计383,966,630股，其中香港联交所上市H股为351,629,020股，未上市普通股为32,337,610股。两类股份数量与上期一致，面值均为每股人民币0.1元，报告期内未发生新增发行、购回、注销或库藏股变动。本次公告由联席公司秘书张巍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662277374","title":"【券商聚焦】中信建投维持劲方医药-B（02595）买入评级 指核心管线推进顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2662277374","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662277374?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:20","pubTimestamp":1787811607,"startTime":"0","endTime":"0","summary":"研发管线方面，GFH375与GFH276分别覆盖KRASG12D及Pan-RAS，构成公司RAS核心管线。GFH925已获批用于经治KRASG12C突变非小细胞肺癌并纳入国家医保目录。中信建投预计2026-2028年公司营业收入分别为1.11亿元、1.29亿元、2.98亿元，维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989698","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","02595","09939","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763644","title":"劲方医药-B(02595.HK)：GFH375(口服KRAS G12D抑制剂)进入一线治疗非小细胞肺癌 II 期研究，将探索单药疗法、联合 EGFR 单抗或化疗的多款治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662763644?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:15","pubTimestamp":1787703316,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09939","BK1161","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116791174","title":"劲方医药-B（02595）GFH375启动一线治疗KRAS G12D突变非小细胞肺癌Ⅱ期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1116791174","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116791174?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:06","pubTimestamp":1787702772,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司8月26日发布自愿公告称，公司自主研发的口服KRAS G12D抑制剂GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌的Ⅱ期研究。此前，GFH375已进入全球首个口服KRAS G12D抑制剂治疗NSCLC的注册性Ⅲ期研究，并在既往公布的I/Ⅱ期单药治疗NSCLC数据显示出“同类最佳”疗效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161075516","title":"劲方医药-B：GFH375步入KRAS G12D突变非小细胞肺癌一线治疗II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1161075516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161075516?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:01","pubTimestamp":1787702470,"startTime":"0","endTime":"0","summary":"劲方医药-B近日宣布，其研发的候选药物GFH375已正式进入一项II期临床研究，旨在评估其作为一线疗法用于KRAS G12D突变型非小细胞肺癌患者的效果。据悉，这项II期研究将重点关注GFH375在初治患者中的安全性、耐受性及初步抗肿瘤活性。劲方医药方面表示，公司对GFH375的临床潜力充满信心，并期待通过后续数据积累，进一步验证其在一线治疗场景中的价值。业内观察人士指出，该研究若能取得积极结果，或将为KRAS G12D突变NSCLC的治疗格局带来深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661257337","title":"劲方医药公布2026中期业绩：现金储备近18亿元，多靶点、多类型全域RAS疗法及联合方案面向胰腺癌、恶病质等大适应症市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2661257337","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661257337?lang=zh_cn&edition=full","pubTime":"2026-08-21 13:57","pubTimestamp":1787291820,"startTime":"0","endTime":"0","summary":"依据弗若斯特沙利文数据，劲方医药拥有全球最全面RAS疗法矩阵之一。目前劲方医药已开发多靶点、多分子形态、一线至各线疗法的全局RAS疗法矩阵，在该赛道有显著的协同、时间、成本优势。全球最全面RAS靶向疗法矩阵之一，面向十年内肿瘤靶向药增速最快赛道 RAS 突变在全球癌症患者中发生率高达30% 。多项单药或联合疗法方案将进一步巩固本公司在RAS靶向疗法赛道的深耕优势、拓宽未来的大适应症商业化协同空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5031198_ZH31198_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5031198_ZH31198_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1161","09939","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661254388","title":"劲方医药（02595）中期股东亏损收窄68.48%至2.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661254388","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661254388?lang=zh_cn&edition=full","pubTime":"2026-08-21 12:21","pubTimestamp":1787286066,"startTime":"0","endTime":"0","summary":"金吾财讯 | 劲方医药（02595）公布截至2026年6月30日止六个月业绩，股东应占亏损2.20亿元人民币，同比亏损收窄68.48%；每股基本亏损0.59人民币元。期内营收4247.3万元人民币，同比减少52.14%。该减少部分由于知识产权授权收入减少7117万元，并部分被药物供应收入增加2601万元所抵消。期内，集团研发开支1.93亿元人民币，同比增长57.25%，主要由于管线数量增加及现有管线的研发投资成本增加。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988979","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","159938","BK1574","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251759","title":"劲方医药-B(02595.HK)发布中期业绩 净亏损2.2亿元 同比收窄68.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251759","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661251759?lang=zh_cn&edition=full","pubTime":"2026-08-21 12:09","pubTimestamp":1787285342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","BK1161","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146926121","title":"劲方医药-B（02595）发布2026年中期业绩：收入4.25亿元 研发投入继续加码","url":"https://stock-news.laohu8.com/highlight/detail?id=1146926121","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146926121?lang=zh_cn&edition=full","pubTime":"2026-08-21 12:05","pubTimestamp":1787285134,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司8月21日公布截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司实现收入42,473千元人民币，较上年同期的88,744千元人民币下降；其他收入及收益40,619千元人民币，同比增加396.56%。报告期内，劲方医药-B的研发开支为192,528千元人民币，高于去年同期的122,435千元人民币；行政开支降低至27,295千元人民币，上年同期为36,952千元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110903702","title":"劲方医药-B：2026年上半年营收达4247万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1110903702","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110903702?lang=zh_cn&edition=full","pubTime":"2026-08-21 12:03","pubTimestamp":1787284988,"startTime":"0","endTime":"0","summary":"劲方医药-B（Genfleet Therapeutics (Shanghai)）披露了截至2026年6月30日的六个月财务数据。报告期内，该公司录得营业收入4247万元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660470368","title":"港股异动 | 劲方医药-B(02595.HK)盘中涨超9% GFH375两款全球首创胰腺癌联合疗法迈入II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2660470368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660470368?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:45","pubTimestamp":1787193956,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","02595","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660471531","title":"劲方医药-B(02595)：GFH375 两款全球首创胰腺癌联合疗法迈入II期研究 包括RAS靶向药联合恶病质双抗方案及不同作用机制的RAS抑制剂双联方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2660471531","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660471531?lang=zh_cn&edition=full","pubTime":"2026-08-20 08:10","pubTimestamp":1787184633,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，董事会欣然宣布一项GFH375的三臂平行对照II期临床研究已于近期启动。GFH375将进入两款全新联合疗法对照单药治疗的II 期研究，治疗KRAS G12D 突变型经治局部晚期不可切除或转移性胰腺癌患者。KRAS G12D 突变在胰腺癌患者中发生率约40%，同时胰腺癌患者的恶病质发生率居于所有瘤种之首、超过60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","BK1515","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482535","title":"Wellington Management Group LLP增持劲方医药-B(02595.HK)2.88万股 每股作价约31.48港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482535","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660482535?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:22","pubTimestamp":1786965727,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","02595","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156453150","title":"劲方医药-B：Wellington Management Group LLP增持，好仓比例升至7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156453150","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156453150?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:11","pubTimestamp":1786957910,"startTime":"0","endTime":"0","summary":"Wellington Management Group LLP于2026年8月13日以每股均价31.4819港元买入劲方医药-B股份2.88万股，涉资约90.67万港元。Wellington Management Group LLP此次增持前持有劲方医药-B好仓2459.98万股，占比6.99%；增持后持股量为2462.86万股，好仓比例升至7.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136722045","title":"财报前瞻｜劲方医药-B本季度营收预计待披露，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1136722045","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136722045?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:46","pubTimestamp":1786668364,"startTime":"0","endTime":"0","summary":"劲方医药-B将于2026年08月21日发布最新季度财报，市场关注临床推进与费用控制对单季亏损的影响及毛利率趋势。由于缺乏覆盖机构在公开渠道披露的本季度一致预期与公司指引，当前市场对劲方医药-B本季度的营收、毛利率、净利润或净利率、调整后每股收益的量化预测暂未形成共识。对劲方医药-B而言，若本季度维持积极推进关键研究节点，短期利润表仍将承压，但也可能带来合作里程碑或授权金的阶段性确认，形成对收入与毛利率的短期支撑。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜劲方医药-B本季度营收预计待披露，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658072876","title":"港股异动 | 劲方医药-B(02595.HK)涨近4% GFH375在国内进入单药治疗非小细胞肺癌注册性III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658072876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658072876?lang=zh_cn&edition=full","pubTime":"2026-08-10 13:44","pubTimestamp":1786340676,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09939","BK1161","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605432","title":"劲方医药-B(02595.HK)：全球首个口服KRAS G12D抑制剂治疗非小细胞肺癌III期研究启动，GFH375第二项注册性临床研究完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658605432?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:13","pubTimestamp":1786320788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","BK1515","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109928638","title":"劲方医药-B（02595.HK）：GFH375进入中国KRAS G12D突变非小细胞肺癌注册性III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1109928638","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109928638?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:02","pubTimestamp":1786320128,"startTime":"0","endTime":"0","summary":"劲方医药-B（GENFLEET-B，股票代码：02595）宣布，其核心在研药物GFH375正式迈入中国注册性III期临床研究阶段，针对的适应症为KRAS G12D突变型非小细胞肺癌（NSCLC）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":-0.1249},{"period":"1month","weight":0.0443},{"period":"3month","weight":-0.0341},{"period":"6month","weight":0.1275},{"period":"1year","weight":0.3879},{"period":"ytd","weight":0.1901}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}